A comprehensive view of Generics / Biosimilars. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Retail & Omnichannel Market Intelligence Service.
Leti Group decreases use of paper by printing QR codes on boxes of its Genven generics for information of interest to doctors, patients, pharmacists, health guilds; pharmacological information of the medicine can be obtained by scanning the code
Published:
May 06, 2024
by CE Noticias Financieras (Latin America)
|
Sandoz resolves patent disputes with Amgen, clearing the way for the launch of its FDA-approved biosimilars, Jubbonti and Wyost, in the US by May 2025; the biosimilars are interchangeable with reference medicines Prolia and Xgeva
Published:
May 06, 2024
by Contify Life Science News
|
Novo Nordisk denies FTC allegations of filing 'junk' patents to prevent competition and elevate prices for its diabetes drug, Ozempic; the company affirms their disputed patents were all approved by the US Patent Office and followed FDA regulations
Published:
May 02, 2024
by Quartz
|
Pfizer’s strong Vyndaqel sales draw attention to rare disease drug’s patent life
Published:
May 01, 2024
by BioPharma Dive
|
FTC cracks down on drug patents
Published:
May 01, 2024
by Becker's Hospital Review
|
Ask us about our Retail & Omnichannel market view